Innova Captab’s Jammu Plant Passes Global Test: Gets GMP Thumbs-Up from Ukraine

Image Source: Linkedln

Ukraine’s SMDC has completed inspection of Innova Captab’s Jammu facility and proposed GMP certification. This milestone boosts the company’s global credibility and export potential. With over 200 international product registrations, Innova Captab is poised for expansion, reinforcing its position as a leading CDMO in the pharmaceutical sector.

Innova Captab Ltd, a rising star in India’s pharmaceutical landscape, is making headlines as Ukraine’s State Medical Drugs Control (SMDC) has completed inspection of its Jammu manufacturing facility and proposed the issuance of a GMP (Good Manufacturing Practice) compliance certificate. This marks a significant step toward expanding the company’s global footprint and regulatory credibility.

Regulatory Progress & Strategic Impact

SMDC Inspection Successfully Completed

Ukraine’s SMDC has concluded its inspection of Innova Captab’s Jammu unit, a critical step in international regulatory approval.
The inspection focused on manufacturing standards, quality control, and facility hygiene, aligning with global pharmaceutical norms.

GMP Compliance Certificate Proposed

Following the inspection, SMDC has proposed granting a GMP certificate to the Jammu facility.
GMP certification is essential for exporting pharmaceutical products to regulated markets, especially in Eastern Europe and CIS countries.

Boost to Export Potential

With GMP approval from Ukraine, Innova Captab can tap into new international markets, enhancing its export portfolio.
The certification also strengthens the company’s credibility with other global regulators, paving the way for future approvals.

Strategic Significance for Innova Captab

Global Expansion Strategy

Innova Captab already operates in over 15 countries and has more than 200 products registered with international authorities.
This certification aligns with its goal to become a leading CDMO (Contract Development and Manufacturing Organization) for global pharma clients.

Investor Confidence & Market Reaction

The news has sparked optimism among investors, with analysts expecting a positive impact on stock performance.
The company’s consistent financial results and expanding regulatory approvals make it a strong contender in the small-cap pharma space.

Jammu Facility’s Role

The Jammu plant is a key manufacturing hub for formulations and APIs.
Its strategic location and infrastructure make it ideal for scaling production and meeting global demand.

Sources: Innova Captab Official Site, Trade Brains, MarketScreener.

Stay Ahead – Explore Now! Carysil Ltd Injects ₹85 Million into Subsidiary Carysil Steel to Accelerate Expansion